Clinical Trial Update: A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of BGB-B2033 alone or with tislelizumab, with or without bevacizumab, in adults with advanced or metastatic solid tumors. Indications include hepa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer
• Yolk Sac Tumor

Drugs mentioned

• BGB-B2033
• Bevacizumab (bevacizumab)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeOne Medicines | Conditions: Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma | Phase 1 | Status: RECRUITING